Headquartered in Fort Myers, FL Fiscal year ends December NASDAQ: NEO neogenomics.com
NeoGenomics, Inc. is a cancer diagnostics company specializing in oncology-focused genetic testing and information services. The company offers one of the most comprehensive oncology testing menus across the cancer continuum, including next-generation sequencing (NGS), cytogenetics, FISH, flow cytometry, immunohistochemistry, and molecular testing. NeoGenomics serves oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing solutions. The company operates a network of CAP-accredited and CLIA-certified laboratories across the United States and a full-service laboratory in Cambridge, United Kingdom. Key growth products include its RaDaR minimal residual disease monitoring platform and expanding NGS capabilities. The company generates revenue primarily through clinical testing services, with a smaller contribution from pharma services and research activities. Updated
Monday's top analyst upgrades and downgrades included Block, Broadcom, CarMax, Deere, Esperion Therapeutics, Marvell Technology, MGM Resorts International, Moderna, Newmont, Vipshop and Wingstop.
Tuesday’s additional top analyst upgrades and downgrades included AutoZone, Bright Health, Etsy, NortonLifeLock and RealReal.
Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Hartford Financial, Nokia, Pinterest, Riot Blockchain and T-Mobile.
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, DexCom, eBay, FireEye, Kraft Heinz, 3M, Pfizer, Seagate Technology, Sonos, Starbucks and T-Mobile.
NeoGenomics, Inc. is a cancer diagnostics company specializing in oncology-focused genetic testing and information services.
The Wall Street consensus 12-month price target for NEO is $21.15.
